Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes

NAActive, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 7, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2027

Conditions
Gestational Diabetes
Interventions
DRUG

Liraglutide 6 MG/ML [Victoza]

Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.

DRUG

Placebos

Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.

Trial Locations (1)

20521

Turku University Hospital, Turku

All Listed Sponsors
lead

Turku University Hospital

OTHER_GOV